ASNC Past President Discusses New ATTRibute-CM Findings

Prem Soman, MD, PhD, MASNC, spoke with Cardiovascular Business about the open-label extension of the ATTRibute-CM trial. 

” … [I]t’s important to go out there and find these patients, diagnose them and treat them. It’s been a remarkable transformation in a field that, less than 10 years ago, we thought it was a rare disease and we had no therapy. Now we know that it’s a prevalent disease. If you look for it, you’ll find it.”

– Prem Soman, MD, PhD, MASNC
ASNC Past President discussing the latest ATTRibute-CM results

In a new video interview with Cardiovascular Business, ASNC Past President Prem Soman, MD, PhD, MASNC, summarized the findings of the open-label extension(OLE) of the ATTRibute-CM trial. Dr. Soman explained the implications of the findings for patients and their physicians.

The OLE evaluated the long-term efficacy and safety of acoramidis through month 54. “In this OLE, we see that, at month 54, early therapy and continuous therapy [with acoramidis] … has a survival advantage both for all-cause mortality and cardiovascular mortality and for cardiovascular hospitalization,” Dr. Soman said. “… It’s important to go out there, find these patients, diagnose them, and treat them.” Dr. Soman also detailed when clinicians should “think of amyloid” during patient evaluations and recommend radionuclide imaging. The clinical trial results were presented at ACC.26 and simultaneously published in JAMA Cardiology.

Watch Interview